spacer
home > ict > spring 2018 > perfecting performance
PUBLICATIONS
International Clinical Trials

Perfecting Performance

The integration of the new ICH E6 (R2) guideline has created many contradictory opinions about what is necessary to be implemented as sponsor oversight in clinical trials to fulfil its requirements. Of course, sponsor oversight in general is not new, but the details to perform mandatory oversight activities and manage compliance for all clinical trial activities are still raising discussions with different opinions and solutions.

Smaller sponsor, biopharmaceutical, and medical device companies moving into early phase clinical trials are especially struggling with the definition and integration of effective study oversight to manage the quality of their research.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Gabriele Faist has more than 28 years' pharma industry experience, with 25 years working in CROs. At the CRO, she was responsible for overseeing clinical drug development programmes, which included line management of a group made up of more than 20, including Project Leaders, Senior Project Leaders, and even Project Assistants, as well as project-related leadership of worldwide multi-functional teams to effectively implement projects, tracking the programme progress to ensure that they are being completed on time and within budget, and maintaining the quality of all work within them.

Heike Schön has more than 25 years of experience in leadership positions in international clinical research and drug development in CROs and biotechnology companies. She has a profound knowledge of clinical drug development processes and regulatory requirements from first-in-human trials to market access. As General Manager, she gained experience in leading and developing a CRO and has successfully implemented her own company, LUMIS International, as Co-Founder and Managing Director. One of her main activities is to support small biotech companies in setting up their clinical
spacer
Gabriele Faist
spacer
spacer
spacer
Heike Schön
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement